An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primatesResearch in context

Summary: Background: Angiopoietin-like protein 4 (ANGPTL4) inhibition is a promising approach to manage atherogenic dyslipidaemia and residual atherosclerotic cardiovascular disease (ASCVD) risk. Human ANGPTL4 loss-of-function (LoF) is associated with reduced plasma triglyceride (TG), remnant chole...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Beryl B. Cummings, Page R. Bouchard, Mark N. Milton, Peter F. Moesta, Vyas Ramanan, John W. Trauger, Eleftheria Maratos-Flier, Andrei Voznesensky, Igor Splawski, Amitabh V. Nimonkar, Keith DiPetrillo, Daniel LaSala, Meihui Pan, Meghan M. Flaherty, Francois Huet, Sukhdeep K. Sahambi, Jijun Dong, Deborah Knee, Regis Cebe, Thomas Huber, Joshua Lehrer-Graiwer, Rebecca A. Juliano, Ethan J. Weiss
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Elsevier 2025-07-01
Ráidu:	EBioMedicine
Fáttát:	MAR001 ANGPTL4 Triglyceride Remnant cholesterol Non-human primates Safety
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S2352396425001926
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!